- HFrEF = EF ≤40%. Four pillars: ARNI · β-blocker · MRA · SGLT2i. Together they cut mortality by ~60%.
- Start all four early, even at low doses. Order matters less than speed.
- Ischemic workup for every new cardiomyopathy.
- ICD if EF ≤35% after ≥90 days of GDMT (≥40 days after MI). CRT if LBBB + QRS ≥150.
- HFimpEF (EF improved >40%) → never stop GDMT.
Pathophysiology in 60 seconds
⌄
- Injured myocardium (MI, toxins, genetic, myocarditis, tachycardia) → low stroke volume.
- The body "defends" BP with RAAS + sympathetic drive + vasopressin → short-term help, long-term harm: fibrosis, remodeling, dilation.
- Each pillar blocks a harmful neurohormone (ARNI, BB, MRA) or unloads the heart and kidney (SGLT2i).
(or ACEi/ARB)
Classification
⌄
| Scheme | Levels |
|---|---|
| ACC/AHA stages | A at risk · B structural disease, no symptoms · C symptoms · D advanced |
| NYHA class | I none · II ordinary activity · III less than ordinary · IV at rest |
| EF | HFrEF ≤40 · HFmrEF 41–49 · HFpEF ≥50 · HFimpEF (was ≤40, now >40) |
The Second Universal Definition of HF (June 2026) moves away from rigid EF cut-offs and stresses cause, trajectory and early detection. Treatment still follows the 2022 guideline until the new AHA/ACC guideline (expected 2027).
Workup — new cardiomyopathy
⌄
TTE · ECG · BNP · BMP, CBC, TSH, iron, A1c, lipids, HIV/hepatitis (selected), ischemic evaluation (cath or CCTA) · cardiac MRI (myocarditis, sarcoid, amyloid, LV thrombus) · alcohol, cocaine, chemo history · genetic testing if family history.
Management — the 4 pillars
⌄
| Drug | Start | Target | Watch |
|---|---|---|---|
| Sacubitril/valsartan | 24/26 mg BID (49/51 if on ACEi/ARB) | 97/103 mg BID | 36 h washout after ACEi; BP, K, Cr; angioedema |
| Carvedilol | 3.125 mg BID | 25 mg BID (50 if >85 kg) | Not in decompensation/shock |
| Metoprolol succinate | 12.5–25 mg daily | 200 mg daily | Only succinate (not tartrate) has HF data |
| Spironolactone | 12.5–25 mg daily | 25–50 mg daily | K <5.0, eGFR >30; gynecomastia → eplerenone |
| Dapagliflozin / empagliflozin | 10 mg daily | 10 mg daily | Genital infection; hold if NPO/sick (euglycemic DKA) |
Soft BP? Start SGLT2i and MRA first (little BP effect), then low-dose BB and ARNI. A small Cr rise (≤30%) after ARNI/MRA/SGLT2i is expected — do not stop.
- Hydralazine + isosorbide dinitrate — self-identified Black patients, NYHA III–IV on GDMT (A-HeFT); or anyone who cannot take ARNI/ACEi/ARB.
- Ivabradine — sinus rhythm, HR ≥70 on max-tolerated BB.
- Vericiguat — recent worsening HF.
- Digoxin — persistent symptoms; target level 0.5–0.9.
- IV iron (ferric carboxymaltose / derisomaltose) — ferritin <100, or 100–299 + TSAT <20%.
- Loop diuretic — for congestion only (symptoms, not survival).
- ICD (primary prevention): EF ≤35%, NYHA II–III, ≥90 days GDMT, ≥40 days post-MI, life expectancy >1 year.
- CRT: EF ≤35%, sinus, LBBB with QRS ≥150 ms (strongest benefit).
- TEER (MitraClip): severe secondary MR despite GDMT (COAPT).
- LifeVest — bridge in selected new cardiomyopathy.
- Non-DHP CCB (diltiazem, verapamil) · NSAIDs · TZDs (pioglitazone) · dronedarone · most antiarrhythmics except amiodarone/dofetilide · saxagliptin.
Pitfalls
⌄
- One drug titrated to max while others never start.
- Stopping BB in stable patients for mild hypotension or fatigue.
- Forgetting the 36-hour ACEi → ARNI washout.
- Stopping GDMT when EF recovers (TRED-HF: relapse).
Board corner
⌄
| Stem | Answer |
|---|---|
| EF 30%, on lisinopril, switch to ARNI | Stop ACEi, wait 36 h |
| EF 30% on GDMT, NYHA II, QRS 160 LBBB | CRT-D |
| Which BB is NOT HFrEF evidence-based? | Metoprolol tartrate, atenolol |
| Black patient, NYHA III on full GDMT | Add hydralazine–ISDN |
| HFrEF + gout → NSAID? | Avoid NSAIDs |
| EF improved 30% → 50% on GDMT | Continue all GDMT |
References
⌄
- Heidenreich PA, et al. 2022 AHA/ACC/HFSA HF guideline. Circulation. 2022;145:e895.
- Maddox TM, et al. 2024 ACC ECDP for HFrEF. J Am Coll Cardiol. 2024;83:1444.
- PARADIGM-HF · DAPA-HF · EMPEROR-Reduced · RALES · COPERNICUS · A-HeFT · TRED-HF.
- Second Universal Definition of Heart Failure. Circulation / JACC. June 2026.